 

Active ingredient: Alogliptin Benzoate; Metformin Hydrochloride 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 


Design: Single dose, two way crossover, in vivo 

Strength: 12.5 mg (base); 1 g 

Subjects: Healthy males and non-pregnant females, general population. 

Additional Comments: 1. Females should practice abstention or contraception during the 
study. 2. To avoid hypoglycemic episodes in healthy volunteers, the drug products should 
be administered with 240 mL of a 20% glucose solution in water, followed by 60 mL of 
the glucose solution administered every 15 minutes for up to 4 hours after dosing. 

 

 

2. Type of study: Fed 


Design: Single dose, two way crossover, in vivo 

Strength: 12.5 mg (base); 1 g (base) 

Subjects: Healthy males and non-pregnant females, general population. 

Additional Comments: Please see above. 

 

 

Analytes to measure: Alogliptin and Metformin in plasma 

 

Bioequivalence based on (90% CI): Alogliptin and Metformin 

 

Waiver request of in vivo testing: Alogliptin 12.5 mg (base); Metformin 500 mg strength 
tablet, based on (i) acceptable bioequivalence studies on the Alogliptin 12.5 mg (base); 
Metformin 1 g strength tablet, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) 
proportional similarity of the formulations across all strengths. 

 

Dissolution test method and sampling times: 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 


